An improved method for quantitative detection of glypican 3
By using glycosaminoglycan degradation enzyme to remove the GAGs side chain of GPC3 and combining the dual anti-sandwich ELISA method, the problems of low sensitivity and complexity of GPC3 detection in the prior art were solved, efficient and accurate detection results were achieved, and liver cells were improved Accuracy of early diagnosis of cancer.
Patent Information
- Application Number
- CN202110618052.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-06-03
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2041-06-03
AI Technical Summary
The existing detection methods of phosphoesterylinositol proteoglycan 3 (GPC3) have problems with low sensitivity, poor reproducibility and time-consuming, especially in serum detection, which affects the accuracy of early diagnosis of hepatocellular carcinoma.
After the GAGs side chain of GPC3 was removed by glycosaminoglycan degradation enzyme, the detection was carried out in combination with the double-anti-sandwich ELISA method, which significantly improved the detection sensitivity and stability and simplified the operation steps.
It significantly improves the sensitivity and stability of GPC3 detection, simplifies the detection process, improves the accuracy of early diagnosis of hepatocellular carcinoma, and can effectively detect GPC3 in complex biological samples, which has important clinical application value.
Smart Images

Figure HDA0003098498750000011 
Figure HDA0003098498750000012 
Figure HDA0003098498750000021
Abstract
Description
Technical Field
[0001] The invention relates to an improved quantitative detection method of glycan 3, belonging to the technical fields of biochemistry and medicine. Background Art
[0002] Proteoglycans (PGs) are a class of biomacromolecules formed by a core protein and one or more glycosaminoglycan (GAG) side chains connected by covalent bonds (Iozzo.1998; Iozzo and Schaefer.2015). Due to the different types of PGs core proteins and the complexity of GAG side chains, the structure of PGs is extremely complex. Similarly, due to the complexity and diversity of GAG side chains, PGs have various important biological functions (Syrokou et al.1999; Baghy.et al.2016; Wight.2018). For example, it regulates cell signal transduction, participates in cell proliferation and differentiation (Mizumoto and Sugahara 2013; Yamada and Sugahara et al. 2008), promotes the occurrence and metastasis of tumors, etc. (Malavaki et al. 2008; Hashiguchi et al. 2010; Esko and Selleck. 2002; Kreuger et al. 2006; Filmus 2001). However, the presence of GAGs also brings great difficulties to the detection of proteoglycans. GAGs are polyanionic linear polysaccharides composed of repeated links of aminohexose disaccharide units, which are easy to interact with various proteins, especially serum contains a large number of proteins and polypeptide substances, which are more likely to lead to the encapsulation of core proteins, thereby interfering with the effective recognition and binding of antibody proteins to core proteins, thereby affecting the detection effect.
[0003] Glypican-3 (GPC3) is an important cell membrane surface proteoglycan and a member of the Glypicans family. It consists of a 70 kDa core protein composed of 580 amino acids and two HS side chains connected near the carboxyl end of the core protein, and is attached to the cell membrane through glycophosphatidylinositol (GPI) anchoring. The mature GPC3 that falls off the cell membrane can generate a 40 kDa amino-terminal subunit and a 30 kDa carboxyl-terminal subunit after furan treatment at the Arg358-Cys359 bond, which are connected by disulfide bonds (De Cat et.al.2003). A large number of studies have shown that GPC3 is specifically expressed in more than 70% of hepatocellular carcinoma (HCC) patients, but is not expressed in tissues of benign lesions, cirrhosis, hepatitis and healthy adults. GPC3 levels are significantly upregulated in HCC tissues and the serum of HCC patients, making GPC3 a specific biomarker for HCC (Haruyama and Kataoka. 2016; Yang et al. 2014).
[0004] At present, a lot of research has been conducted on the detection methods of GPC3 at home and abroad, and a series of important research results have been achieved. Yu et al. established a chemiluminescent immunoassay, Zhang et al. developed a competitive radioimmunoassay, Zhao et al. constructed and applied the aptamer-mediated USPIO (Apt-USPIO) probe for Glypican-3 (GPC3) targeted imaging technology, and the aptamer nanobiosensor method founded by Li Guiyin in 2020 specifically detected GPC3. However, in practical applications, enzyme-linked immunosorbent assay is still the most commonly used detection method for GPC3 detection. The GPC3 sandwich ELISA method established by Filmus Laboratory is currently the commonly used method for serum GPC3 detection in clinical diagnosis and research of HCC (Capurro.et al.2003). However, conventional ELISA has the disadvantages of low sensitivity, poor reproducibility and time-consuming in GPC3 detection, which hinders the application of this method in the clinical diagnosis of HCC. Especially in the early stage of hepatocellular carcinoma (HCC), the content of GPC3 in serum is extremely low, and the complex components in serum make it very difficult to be used in the early clinical diagnosis of HCC. Therefore, it is urgent to improve the GPC3 ELISA method.
[0005] From the molecular structure of GPC3, at least one GAGs polysaccharide chain with a high negative charge is covalently bound to the GPC3 core protein. The steric hindrance caused by the presence of GAGs side chains seriously interferes with the binding of antibodies to the recognition sites on the core protein. In addition, as mucopolysaccharides, GAGs side chains are very easy to interact and bind with various biomacromolecules such as proteins in the blood, resulting in the encapsulation of the core protein, thereby further interfering with the effective recognition and binding of antibodies to the GPC3 core protein. This should be the main reason for the low sensitivity and time-consuming nature of the traditional ELISA method for detecting PGs in serum. Summary of the invention
[0006] In view of the deficiencies of the prior art, the present invention provides an improved quantitative detection method for glypican 3. The detection method provided by the present invention utilizes a GAGs-specific degrading enzyme to remove the GAGs side sugar chains of GPC3 and then utilizes a traditional sandwich ELISA method for detection, which can solve the shortcomings of the traditional GPC3 enzyme-linked immunosorbent assay method, such as cumbersome operation steps, low detection sensitivity, poor result reproducibility, and time-consuming, and provides a practical solution and technology for the detection of GPC3 in complex biological samples such as serum, and has important practical value in proteoglycan-related research and clinical applications.
[0007] The technical solution of the present invention is as follows:
[0008] An improved method for quantitatively detecting glypican 3 comprises the following steps:
[0009] (1) adding glycosaminoglycan degrading enzyme to the sample to be tested, and performing enzymatic hydrolysis at 25 to 45° C. for 20 to 60 minutes to obtain the sample to be tested after enzyme treatment;
[0010] (2) detecting the absorbance of the sample to be tested after the enzyme treatment in step (1) by double antibody sandwich ELISA method;
[0011] (3) preparing a phosphatidylinositol proteoglycan 3 standard into a standard solution with a concentration of 10 μg / mL, and then diluting the standard solution with a buffer solution by a gradient of 80, 160, 320, 640, 1280, 2560, and 5120 times to obtain a standard gradient solution, and then measuring the absorbance of the standard gradient solution according to the method of steps (1) and (2), and drawing a standard curve according to the gradient concentration of the standard gradient solution and the measured absorbance;
[0012] (4) Calculate the content of glypican 3 in the sample according to the absorbance of the sample obtained in step (2) and the standard curve obtained in step (3).
[0013] Preferably, according to the present invention, the sample to be tested in step (1) is a glypican 3 solution or body fluid;
[0014] Further preferably, the body fluid is serum or plasma.
[0015] Preferably according to the present invention, the glycosaminoglycan degrading enzyme in step (1) is one of heparin degrading enzyme and chondroitin sulfate degrading enzyme, or a mixture of both.
[0016] Further preferably, the glycosaminoglycan degrading enzyme is a mixture of heparin degrading enzyme (Heparinase, Hepase) and chondroitin sulfate degrading enzyme (Chondroitinase, Chase) of microbial origin, and the mass ratio of heparin degrading enzyme Hepase to chondroitin sulfate degrading enzyme Chase is 1:(1-2).
[0017] Preferably according to the present invention, the mass volume ratio of the glycosaminoglycan degrading enzyme and the sample to be tested in step (1) is (1-5):80, unit: μg / μL.
[0018] Preferably, according to the present invention, the temperature in step (1) is 30-40° C. and the time is 30-50 min.
[0019] Preferably, according to the present invention, the specific operation of the double antibody sandwich ELISA method in step (2) is as follows:
[0020] a. Capture antibody coating: dilute the anti-GPC3 monoclonal antibody to a concentration of 20-80 ng / μL, add 50 μL to the wells of the ELISA plate and incubate at 4°C for 4-12 hours;
[0021] b. Blocking: Discard the liquid in the wells, add 100-200 μL of blocking solution and block for 0.5-2 hours at room temperature;
[0022] c. Add antigen: add 50-100 μL of the sample to be tested after enzyme treatment to the wells of the ELISA plate and incubate at room temperature for 0.5-2 hours before washing the plate;
[0023] d. Detection antibody: dilute the anti-GPC3 camel polyclonal antibody 1000-5000 times, take 50 μL and add it to the wells of the ELISA plate and incubate at room temperature for 0.5-2 h;
[0024] e. Washing the plate: dilute the enzyme-labeled antibody 20,000 to 100,000 times with buffer, take 50 μL and add it to the wells of the enzyme-labeled plate and incubate at room temperature for 10 to 30 minutes before washing the plate;
[0025] f. Color development: Add 50-100 μL TMB color development solution to the reaction wells of the ELISA plate and develop the color for 15-20 minutes at room temperature in the dark;
[0026] g. Stop: Add an equal volume of stop solution (1M HCl) to the wells of the ELISA plate and measure the absorbance of the sample at 450 nm using an ELISA reader within 15 minutes.
[0027] According to the present invention, the buffer in step (3) is NaAc-HAc buffer.
[0028] Preferably, according to the present invention, the method for preparing the anti-GPC3 camel polyclonal antibody in step d is as follows:
[0029] i) Using molecular biological methods to identify GPC3C 359-580 The gene sequence was constructed into the pTracer expression vector and transfected into HEK293T cells in good growth condition;
[0030] ii) using nickel column affinity chromatography to purify the GPC3 secreted by HEK293T cells in step i) to obtain the carboxyl-terminal protein GPC3C as an antigen;
[0031] iii) Prepare a healthy camel, collect 5 mL of venous blood sample before immunization, place the drawn blood sample at room temperature for about 2 hours, and place the blood sample at 4°C overnight after it coagulates into a blood clot to allow the serum to completely precipitate, centrifuge at 2000 rpm / min at 4°C for 10 minutes, discard the precipitate, take the supernatant and store it at -80°C for later use;
[0032] iv) adding PBS buffer to 0.1-0.5 mg of the antigen in step ii) to make the final volume 2 mL, and fully emulsifying the antigen solution with an equal volume of Freund's complete adjuvant (CFA);
[0033] v) Inject the emulsion of antigen at multiple points on the camel's back for primary immunization, 0.1-0.4 mL / point;
[0034] vi) performing booster immunization every 2 to 3 weeks, for a total of 3 booster immunizations; the emulsification of the booster immunization antigen is the same as step iv), wherein incomplete Freund's adjuvant (IFA) is used instead of complete Freund's adjuvant (CFA) as the immune adjuvant;
[0035] vii) Two weeks after the second booster immunization, 200-300 mL of blood sample is collected from the camel ear vein, and the serum is separated according to the method described in step iii). The supernatant obtained in step iii) is used as the control group, and the antibody titer is detected by ELISA. When the antibody titer reaches more than 10,000, a large amount of camel polyclonal antibodies against GPC3 can be collected.
[0036] The improved detection method of glypican 3 of the present invention is used in the early clinical diagnosis of hepatocellular carcinoma.
[0037] Preferably, the specific method of the application is as follows:
[0038] ① Collect serum samples from patients, add a mixture of heparin degrading enzyme and chondroitin sulfate degrading enzyme to the serum samples, and perform enzymatic hydrolysis at 25-45°C for 20-60 minutes to obtain enzyme-treated serum samples;
[0039] Among them, the mass ratio of heparin degrading enzyme to chondroitin sulfate degrading enzyme is 1:1;
[0040] ② Use double antibody sandwich ELISA method to detect the absorbance of the serum sample treated with enzyme in step ①;
[0041] ③ Mix equal volumes of serum from 20 healthy subjects as serum standards, mix GPC3 in the serum of healthy subjects to prepare a serum standard solution with a concentration of 10 μg / mL, then use a buffer to perform a gradient dilution of the serum standard solution by 80, 160, 320, 640, 1280, 2560, and 5120 times to obtain a serum standard gradient solution, and then determine the absorbance of the serum standard gradient solution according to the method of steps ① and ②, and draw a standard curve according to the concentration of the serum standard gradient solution and the measured absorbance;
[0042] ④ According to the absorbance of the serum sample obtained in step ② and the standard curve obtained in step ③, the content of glycan 3 in the patient's serum sample is calculated to provide a basis for the early clinical diagnosis of hepatocellular carcinoma.
[0043] According to the present invention, the buffer in step ③ is NaAc-HAc buffer.
[0044] The molecular biological methods described in the present invention are all conventional molecular biological techniques. 359-580 The NCBI accession number of the gene sequence is Gene ID: 2719.
[0045] Beneficial effects:
[0046] 1. The present invention first degrades the two HS side chains of the carboxyl end of the core protein of GPC 3 with glycosaminoglycan degrading enzyme, and then detects by double-antibody sandwich ELISA method, which can significantly improve the sensitivity, stability and specificity of GPC 3 detection, and the quantitative detection line is pg level. The problems of complicated operation steps, long time consumption, low detection sensitivity and poor result reproducibility in the existing GPC 3 detection process are effectively solved. Practical solutions and technologies are provided for the detection of GPC3 in complex biological samples such as serum, which has important practical value in proteoglycan related research and clinical application. And because it is simple to operate, the method of the present invention can also be applied to the quantitative detection of other proteoglycans.
[0047] 2. The detection method provided by the present invention can be applied to the early clinical diagnosis of patients with hepatocellular carcinoma, and the positive detection rate of HCC patients is significantly improved. BRIEF DESCRIPTION OF THE DRAWINGS
[0048] Figure 1 It is a schematic diagram of the principle of the detection method of the present invention;
[0049] Figure 2 This is a bar graph showing the sensitivity of different glycosaminoglycan degrading enzymes to GPC3 detection.
[0050] Figure 3 This is the standard curve of GPC3 content and absorbance in the buffer solution of Example 2 of the present invention.
[0051] Figure 4 This is the standard curve of GPC3 content and absorbance in the serum sample of Example 3 of the present invention.
[0052] Figure 5 Result diagram of clinical sample detection in Example 4 of the present invention.
[0053] Figure 6 A comparison chart of the detection method of the present invention and the traditional sandwich ELISA method for detecting HCC patient samples. DETAILED DESCRIPTION
[0054] In order to make the technical problems, technical solutions and advantages to be solved by the present invention clearer, the following will be described in detail with reference to the accompanying drawings and specific embodiments. The following embodiments are described to fully disclose some common techniques for implementing the present invention, rather than to limit the scope of application of the present invention.
[0055] For the chondroitin sulfate degrading enzyme HCLase used in the following examples, please refer to the article Han, W., Wang, W., Zhao, M., Sugahara, K., & Li, F. (2014). A novel eliminase from a marine bacterium that degrades hyaluronan and chondroitin sulfate. The Journal of biological chemistry, 289(40), 27886–27898.
[0056] Heparin degrading enzyme Hepase is a commercially available product.
[0057] Chondroitin sulfate degrading enzyme Chase comes from intestinal microorganisms and is obtained by conventional enzyme extraction methods.
[0058] Example 1: Screening of glycosaminoglycan degrading enzymes suitable for enzymatic hydrolysis of glypican 3
[0059] GPC3 was prepared into a GPC3 solution with a concentration of 1 mg / mL in phosphate buffer, and then the GPC3 solution was divided into groups 1-7, with 160 μL in each group; among them, group 1 did not add glycosaminoglycan degrading enzyme, which was the control group; group 2 added 6 μg heparin degrading enzyme Hepase, group 3 added 6 μg chondroitin sulfate degrading enzyme Chase, group 4 added 6 μg chondroitin sulfate degrading enzyme HCLase, group 5 added 3 μg heparin degrading enzyme Hepase and 3 μg chondroitin sulfate degrading enzyme Chase, group 6 added 3 μg heparin degrading enzyme Hepase and 3 μg chondroitin sulfate degrading enzyme HCLase, and group 7 added 2 μg heparin degrading enzyme Hepase, 2 μg chondroitin sulfate degrading enzyme Chase and 2 μg chondroitin sulfate degrading enzyme HCLase.
[0060] The 1-7 groups were reacted at 30°C for 50 min to obtain enzyme-treated GPC3 samples, and then the OD values of the enzyme-treated GPC3 samples were detected using the double antibody sandwich ELISA method. The test results are as follows: Figure 2 shown.
[0061] Depend on Figure 2 It can be seen that heparin degrading enzyme Hepase, chondroitin sulfate degrading enzyme Chase and chondroitin sulfate degrading enzyme HCLase can all improve the detection sensitivity of GPC3, among which the detection sensitivity of GPC3 treated with heparin degrading enzyme Hepase and chondroitin sulfate degrading enzyme Chase is the highest.
[0062] The specific operation steps of the double antibody sandwich ELISA detection method in this embodiment are as follows:
[0063] a. Capture antibody coating: dilute the anti-GPC3 monoclonal antibody to a concentration of 50 ng / μL, add 50 μL to the wells of the ELISA plate and incubate at 4°C for 12 h;
[0064] b. Blocking: Discard the liquid in the well, add 200 μL of blocking solution and block for 2 h at room temperature;
[0065] c. Add antigen: add 100 μL of enzyme-treated GPC3 solution to the wells of the ELISA plate and incubate at room temperature for 1 hour before washing the plate;
[0066] d. Detection antibody: dilute the anti-GPC3 camel polyclonal antibody 2000 times, take 50 μL and add it to the wells of the ELISA plate and incubate at room temperature for 2 h;
[0067] e. Washing the plate: dilute the enzyme-labeled antibody 50,000 times with buffer, add 50 μL to the wells of the enzyme-labeled plate and incubate at room temperature for 30 minutes before washing the plate;
[0068] f. Color development: Add 100 μL TMB color development solution to the reaction wells of the ELISA plate and develop the color for 20 min at room temperature in the dark;
[0069] g. Stop: Add an equal volume of stop solution (1M HCl) to the wells of the ELISA plate and measure the absorbance of the sample at 450 nm using an ELISA reader within 15 minutes.
[0070] Wherein, the preparation method of the anti-GPC3 camel polyclonal antibody in step d is as follows:
[0071] i) Using molecular biological methods to identify GPC3C 359-580 The gene sequence was constructed into the pTracer expression vector and transfected into HEK293T cells in good growth condition;
[0072] ii) using nickel column affinity chromatography to purify the GPC3 secreted by HEK293T cells in step i) to obtain the carboxyl-terminal protein GPC3C as an antigen;
[0073] iii) Prepare a healthy camel, collect 5 mL of venous blood sample before immunization, place the drawn blood sample at room temperature for about 2 hours, and place the blood sample at 4°C overnight after it coagulates into a blood clot to allow the serum to completely precipitate, centrifuge at 2000 rpm / min at 4°C for 10 minutes, discard the precipitate, take the supernatant and store it at -80°C for later use;
[0074] iv) adding PBS buffer to 0.5 mg of the antigen in step ii) to make the final volume 2 mL, and fully emulsifying the antigen solution with an equal volume of Freund's complete adjuvant (CFA);
[0075] v) Inject the antigen emulsion at multiple sites on the camel's back for primary immunization, 0.2 mL / site;
[0076] vi) performing booster immunization every 2 weeks, for a total of 3 booster immunizations; the emulsification of the booster immunization antigen is the same as step iv), wherein incomplete Freund's adjuvant (IFA) is used instead of complete Freund's adjuvant (CFA) as the immune adjuvant;
[0077] vii) Two weeks after the second booster immunization, 200-300 mL of blood sample is collected from the camel ear vein, and the serum is separated according to the method described in step iii). The supernatant obtained in step iii) is used as the control group, and the antibody titer is detected by ELISA. When the antibody titer reaches more than 10,000, a large amount of camel polyclonal antibodies against GPC3 can be collected.
[0078] Example 2: Detection of GPC3 in Buffer
[0079] The purified GPC3 was dissolved in phosphate buffer to prepare a sample with a concentration of 10 μg / mL, and then diluted with NaAc-HAc buffer (100 mM NaCl, 10 mM NaAc-HAc, pH 5.0) by a gradient of 80, 160, 320, 640, 1280, 2560, and 5120 times, respectively. 3 μg of heparin degrading enzyme Hepase and 3 μg of chondroitin sulfate degrading enzyme Chase were added to the reaction tubes, respectively, and the reaction was carried out at 30°C for 30 minutes to obtain enzyme-treated GPC3 solutions of different concentrations. The absorbance of GPC3 was detected by double antibody sandwich ELISA using the enzyme-treated GPC3 solutions of different concentrations.
[0080] The double antibody sandwich ELISA method described in this example is the same as that in Example 1.
[0081] In this example, the absorbance value is significantly linearly correlated with the GPC3 content in the buffer solution, and the standard curve is y=0.0266x+0.0112(R 2 =0.9989), as Figure 3 shown.
[0082] By calculation, it can be concluded that the maximum detectable amount in this embodiment is 0.56 pg, that is, the detection sensitivity can reach the pg level. This shows that GPC3 treated with glycosaminoglycan degrading enzyme can expose the specific binding sites on the core protein, improve the binding efficiency of the antibody and GPC3, and improve the detection sensitivity.
[0083] Example 3: Detection of GPC3 in serum samples
[0084] Equal volumes of sera from 20 healthy subjects were mixed as serum samples, and GPC3 was mixed with the serum of healthy subjects to prepare a sample with a concentration of 10 μg / mL. The sample was then gradiently diluted with NaAc-HAc buffer (100 mM NaCl, 10 mM NaAc-HAc, pH 5.0) by 80, 160, 320, 640, 1280, 2560, and 5120 times, respectively, to obtain a gradient solution of healthy subject serum + GPC3.
[0085] 3 μg of heparin degrading enzyme Hepase and 3 μg of chondroitin sulfate degrading enzyme Chase were added to the gradient solution of healthy human serum + GPC3, and enzymatic hydrolysis was performed at 30°C for 40 minutes to obtain the gradient solution of healthy human serum + GPC3 after enzyme treatment. The absorbance of glycan 3 was detected by double antibody sandwich ELISA method using the gradient solution of healthy human serum + GPC3.
[0086] The double antibody sandwich ELISA method described in this example is the same as that in Example 1.
[0087] A standard curve between GPC3 content and absorbance was constructed based on the OD value of the gradient solution of healthy human serum + GPC3 and the known concentration. The results are as follows Figure 4 shown.
[0088] Depend on Figure 4 It can be seen that with the increase of GPC3 content, the absorbance value gradually increases and can show a significant linear relationship. The standard curve formula is y=0.0036x+0.1106(R 2 =9859), wherein x is the concentration of GPC3, y is the absorbance value, and it can be concluded through calculation that when this method is used to detect the content of GPC3 in serum, a maximum of 5.53 pg can be detected, which is slightly lower than the sensitivity of the detection of GPC3 content in Example 2, but the detection sensitivity can still reach the pg level.
[0089] Example 4: Detection of GPC3 in clinical samples
[0090] Serum samples from 41 hepatocellular carcinoma patients, 31 liver cirrhosis patients and 29 healthy subjects were diluted 10 times and used as test samples.
[0091] An improved method for quantitatively detecting glypican 3 comprises the following steps:
[0092] (1) Add 3 μg of heparin degrading enzyme Hepase and 3 μg of chondroitin sulfate degrading enzyme Chase to 160 μL of the sample to be tested, and perform enzymatic hydrolysis at 35° C. for 40 min to obtain the enzyme-treated sample to be tested;
[0093] (2) using the double antibody sandwich ELISA method to detect the absorbance of GPC3 using the sample to be tested after the enzyme treatment in step (1);
[0094] (3) Then, the content of GPC3 in the sample to be tested is calculated using the OD value of the sample to be tested obtained in step (2) and the standard curve constructed in Example 3.
[0095] The double antibody sandwich ELISA method in step (2) is the same as that in Example 1.
[0096] The test results of absorbance in this embodiment are as follows Figure 5 As shown by Figure 5It can be seen that the average OD450 nm detection value of 41 HCC patients was 0.56±0.31 (GPC3 concentration was 124.8 ng / mL), the average OD450 nm detection value of 31 cirrhosis patients (CH) was 0.264±0.109 (GPC3 concentration was 42.61 ng / mL), and the average OD450 nm detection value of sera from 29 healthy people (NL) was 0.194±0.075 (GPC3 concentration was 23.17 ng / mL).
[0097] Through data analysis, the mean value of OD450nm readings in the benign liver disease group plus two times the standard deviation value of 0.482 (i.e., the concentration of GPC3 is 103.17ng / mL) is used as the lower limit of HCC detection. 61% (25 / 41) of the samples are higher than this value, and the positive rate of detection is 61%. The positive detection rate of the improved sandwich ELISA is higher than the positive detection rate of 56% (53-59%) of other detection methods (Tangkijvanich, P. et al. 2010, Capurro, M. 2003). This shows that the improved GPC3 enzyme-linked immunosorbent assay can be used in the clinical prediction of patients with liver cirrhosis and the early diagnosis of patients with liver cancer.
[0098] Example 5: Comparison between the detection method of the present invention and the traditional sandwich ELISA method
[0099] Serum samples from 10 HCC patients were taken as test samples, and the test samples were divided into an experimental group and a control group.
[0100] Then, the experimental group was subjected to GPC3 detection according to the method of Example 4, and the control group was tested by conventional sandwich ELISA after adding a buffer having the same mass as that of the experimental group's heparin degrading enzyme Hepase and chondroitin sulfate degrading enzyme Chase.
[0101] The test results of this embodiment are as follows Figure 6 As shown by Figure 6 It can be seen that the absorbance value of the serum samples of HCC patients treated with glycosaminoglycan degrading enzyme increased significantly, and the specificity and sensitivity were significantly improved, indicating that the detection sensitivity of the improved GPC3 detection method provided by the present invention is significantly better than that of the traditional sandwich ELISA method.
Claims
1. A method for quantitative detection of glypican 3 for non-disease diagnosis purposes, characterized in that: The steps include: (1) Add glycosaminoglycan degrading enzyme to the sample to be tested, and perform enzymatic hydrolysis at 25-45°C for 20-60 min to obtain the enzyme-treated sample to be tested; Wherein, the glycosaminoglycan degrading enzyme is a mixture of heparin degrading enzyme and chondroitin sulfate degrading enzyme, the mass ratio of heparin degrading enzyme to chondroitin sulfate degrading enzyme is 1:(1-2); the mass volume ratio of the glycosaminoglycan degrading enzyme to the sample to be tested is (1-5):80, unit: μg / μL; (2) The sample to be tested after the enzyme treatment in step (1) is subjected to absorbance detection by double antibody sandwich ELISA method. The specific operation of the double antibody sandwich ELISA method is as follows: a. Capture antibody coating: dilute the anti-GPC3 monoclonal antibody to a concentration of 20-80 ng / μL, add 50 μL to the wells of the ELISA plate and incubate at 4°C for 4-12 h; b. Blocking: Discard the liquid in the well, add 100~200 μL of blocking solution and block for 0.5~2 h at room temperature; c. Add antigen: add 50~100 μL of the sample to be tested after enzyme treatment to the wells of the ELISA plate and incubate at room temperature for 0.5~2 h before washing the plate; d. Detection antibody: dilute the camel polyclonal antibody against GPC3 1000-5000 times, take 50 μL and add it to the wells of the ELISA plate and incubate at room temperature for 0.5-2 h; e. Washing the plate: dilute the enzyme-labeled antibody 20,000-100,000 times with buffer, add 50 μL to the wells of the enzyme-labeled plate and incubate at room temperature for 10-30 min before washing the plate; f. Color development: Add 50-100 μL TMB color development solution to the wells of the ELISA plate and develop the color for 15-20 min at room temperature in the dark. g. Stop: Add an equal volume of stop solution 1M HCl to the wells of the ELISA plate and measure the absorbance of the sample at 450 nm using an ELISA reader within 15 min; Wherein, the preparation method of the anti-GPC3 camel polyclonal antibody in step d is as follows: i) Using molecular biological methods to identify GPC3C 359-580 The gene sequence was constructed into the pTracer expression vector and transfected into HEK293T cells in good growth condition; ii) using nickel column affinity chromatography to purify the GPC3 secreted by HEK293T cells in step i) to obtain the carboxyl-terminal protein GPC3C as an antigen; iii) Prepare a healthy camel and collect 5 mL of venous blood sample before immunization. Place the drawn blood sample at room temperature for 2 h. After the blood sample has coagulated into a blood clot, place it at 4 °C overnight to allow the serum to completely precipitate. Centrifuge at 2000 rpm / min for 10 min at 4 °C, discard the precipitate, take the supernatant and store it at -80 °C for later use; iv) Add PBS buffer to 0.1-0.5 mg of the antigen prepared in step ii) to a final volume of 2 mL, and fully emulsify the antigen solution with an equal volume of Freund's complete adjuvant; v) Inject antigen emulsion at multiple points on the camel's back for primary immunization, 0.1-0.4 mL / point; vi) boosting immunization every 2 to 3 weeks, for a total of 3 times; the emulsification of the boosting immunization antigen is the same as step iv), except that Freund's incomplete adjuvant is used instead of Freund's complete adjuvant as the immune adjuvant; vii) 2 weeks after the second booster immunization, 200-300 mL of blood sample is collected from the camel ear vein, and the serum is separated according to the method described in step iii). The supernatant obtained in step iii) is used as the control group, and the antibody titer is detected by ELISA. When the antibody titer reaches more than 10,000, a large amount of camel polyclonal antibodies against GPC3 can be collected; (3) Prepare a standard solution with a concentration of 10 μg / mL of the phosphatidylinositol proteoglycan 3 standard, and then use a buffer to perform a gradient dilution of the standard solution by 80, 160, 320, 640, 1280, 2560, and 5120 times to obtain a standard gradient solution, and then determine the absorbance of the standard gradient solution according to the method of steps (1) and (2), and draw a standard curve based on the gradient concentration of the standard gradient solution and the measured absorbance; (4) Calculate the content of glycan 3 in the sample according to the absorbance of the sample obtained in step (2) and the standard curve obtained in step (3).
2. The method for quantitative detection of glypican 3 according to claim 1, characterized in that: The sample to be tested in step (1) is a phosphatidylinositol proteoglycan 3 solution.
3. The method for quantitative detection of glypican 3 according to claim 1, characterized in that: In step (1), the enzymatic hydrolysis temperature is 30-40°C and the time is 30-50 min.
